Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Retained Earnings (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Retained Earnings data on record, last reported at -$273.1 million in Q4 2025.

  • For Q4 2025, Retained Earnings fell 111.14% year-over-year to -$273.1 million; the TTM value through Dec 2025 reached -$273.1 million, down 111.14%, while the annual FY2025 figure was -$273.1 million, 111.14% down from the prior year.
  • Retained Earnings reached -$273.1 million in Q4 2025 per TRDA's latest filing, down from $621000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $621000.0 in Q3 2025 and bottomed at -$273.1 million in Q4 2025.
  • Average Retained Earnings over 4 years is -$108.9 million, with a median of -$129.9 million recorded in 2024.
  • Peak YoY movement for Retained Earnings: tumbled 26205.44% in 2024, then skyrocketed 100.48% in 2025.
  • A 4-year view of Retained Earnings shows it stood at -$188.3 million in 2022, then decreased by 3.55% to -$195.0 million in 2023, then skyrocketed by 33.66% to -$129.3 million in 2024, then tumbled by 111.14% to -$273.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$273.1 million in Q4 2025, $621000.0 in Q3 2025, and -$189.8 million in Q2 2025.